drugset / Trial / NCT00287456
Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
We hypothesize use of the insulin pump will improve body weight, lean body mass, whole body protein turnover, hepatic glucose production (HGP), and blood sugar control in CF patients with impaired glucose tolerance or patients with CF related diabetes (CFRD). We further hypothesize that HGP is also elevated in children/adolescents with type 1 diabetes and that the insulin pump will result in decreased HGP.
Timeline
- Start
- 2006-02-02
- Primary completion
- 2006-02-02
- Completion
- 2006-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Insulin | Protein / enzyme biologic | — | Subcutaneous |